Mo u may be correct from a sensitivity pov, but the moment
Mo u may be correct from a sensitivity pov, but the moment Shawn Wolfe went onto a Public Forum where he's previously posted his Business and Personal opinions including BUS PHONE NUMBERS and gave an ACCOUNTING of either himself or his Mother as becoming sick with Covid-19 he became a person who is under the microscope to validate what hes posted.
I personally will not call him and ask him questions about the drug and quite Honestly like you requested I hope NO ONE does, but the cats out of the bag on BRIL! There are forces working to KILL this DRUG!
We are Blessed that its been studied at major Universities now like GMU, that DOD through BARDA are now in play..thats opened its evaluation up and should protect it going forward! At this point we are DATA DRIVEN and pending....
I personally have posted about BRIL on my own FB account...my posts are in regards to the FDA sitting on this drug, when they know the data is good and at the same time our Government is MANDATING VACCINES and "reporting + tests" as a record on all US citizens. Im troubled that Congress has a spending bill for $3.2Trillion and Ive seen NO $$$ earmarked to support IPIX to help them along w/ a DRUG THAT SAVES LIVES, all along the same FEDS can allocate money for TREES and BRIDGES TO NOWHERE...
Having worked 33 years in Big Pharma I have no love lost for FDA..they have FAILED us many times over the years...if any org of the Federal Government can screw up BRIL, an NDA..a right to try initiative it will be our own FDA...former head of FDA Gottleib has written a book about it...https://www.msn.com/en-us/news/us/former-fda-commissioner-we-remain-almost-equally-vulnerable-to-threat-from-the-next-pandemic/ar-AAOt6Q6...the Feds are very POLITICAL over Covid and have BLOWN IT BADLY...in fact they take $$$ from Big Pharma to "approve" their applications at the expense of small Cos like IPIX...this happens regularly!
We may have an advantage this time around based on previous History of the drug, and the fact that DOD/BARDA potentially imo is involved w/ this drug!
What concerns me the most is that Government agencies seem more VACCINE ORIENTED as apposed to TREATMENT oriented!
I worry that our great little drug BRIL could be DERAILED by a Big Pharma (or an FDA official from INSIDE)...who is working w/ the FDA on their own Treatments a la PFIZER as an example.I Can tell you all the LOBBY ISTS in DC are working hard to push VACCINES only and the Feds want to MANDATE THEM. NEW TREATMENTs ARE EXPENSIVE...Vaccines are not...Im NOT an anti-vaxer.. I believe in choice.I know Docs in DC who swear by Hydroxychoroquine at HIGH DOSE early on in OP treatment in Covid and the FDA has SHUT IT DOWN! We have major Hospital Groups like Henry Ford in Detroit that SWEAR BY HYDROXY as a good working repurposed med..it cost PENNIES a day...thats the issue...no $$$ to support it..thats the rub..thats big pharma influence!
They(the FEDS) do not support docs and OFF LABEL USE and REPURPOSing meds...I have posted already about anti-PDE4 and Hydroxychloroquine where that MOA and HIGH DOSE is likely why it works even though the drug is an AntiParasitic, through a strong Compliment Cascade effect!
The FDA and Dr Fauci and CDC and many others have Totally squelched this application of Hydroxychoroquine and in my mind that supports my argument!
We will likely be ok...but the risks and politics are against us!
If the Feds wanted to CURE THIS VIRUS they had in their power to do so many months ago! Thats why I believe WE SHOULD PUSH BACK HARD NOW..get the word out to all MEDIA..expose the TRUTH as we know it.
That being said, I mostly agree with you that we should not bother the Shawn Wolfes of this World! But we also should not TRUST the Feds to do the right thing!
GLTA longs!
RP
7
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Tech-Boost for a Community Farm Vision Seems like everyone's buzzing about sustainability these days, and why not? It's the way forward. Take 4Roots and their Farm Campus initiative in Orlando. They've hooked up with Managed Services Group (MSG) to bolster their tech backbone, raising the stakes for their mission to shake up the food system. It's a no-nonsense...
Continue Reading
Unpacking the Ambitious 90-Day Plan When you hear Vishal Garg's name next to a 90-day sprint plan, it's not your everyday boardroom shuffle—you know there's grit behind the screen. Better Home & Finance (BETR) is angling for a massive turnaround with its latest rollout, but whether it's all sizzle and no steak is what we're here to figure out. Financial Metrics and...
Continue Reading
Action Time for Photronics Investors There's nothing like a looming deadline to get the adrenaline pumping, especially when you're staring down the barrel of a federal securities class action. Photronics, Inc. (NASDAQ: PLAB) has found itself tangled in legal webs, with the clock ticking down to September 4, 2026. That’s the deadline for investors to move on being the...
Continue Reading
What's Cooking at Hotel Zetta? Ever see a company shake up an event like TELUS Digital is about to at Dreamforce 2026? Instead of the usual booth schmooze-fest at Moscone Center, these folks are camping at Hotel Zetta with a packed 'boutique' agenda. From September 15–16, they're rolling out serious insider sessions for the big brains in financial services, education,...
Continue Reading
Sizing Up the Legal Stakes for Wise Group Alright, here's a doozy that's bound to get your attention if you've got a stake in Wise Group plc (NASDAQ: WSE). We're talking about a looming securities class action, with the deadline to get involved barreling down like a runaway freight train. Before September 29, 2026, to be exact—mark it, circle it, do whatever you have to...
Continue Reading
Revamping Streetwear with PLAY Palm Angels and Pacsun In a move that's making waves from the fashion runways straight into the heart of youth culture, PLAY Palm Angels is swooping into Pacsun, and they’re not just strolling in—they’re parading with a 41-piece fashion collection. Not to mention, they've snagged Avani Gregg, a powerhouse cultural influencer, to strut...
Continue Reading
Meet “Tahoe Truckee Life” Kane Schaller, the face of the Tahoe Truckee Life series, is giving folks a front-row seat to the lives and landscapes that make the Reno-Tahoe region buzz. Now, I've seen shows trying to pull this off, but this one might just spark something genuine if done right. The Real Deal on Reno-Tahoe The show airs on the REAL Shows Network—a...
Continue Reading
Faith and Tech: An Unexpected Alliance? Alright, here's something that'll make you sit up: Catholic college grads are not just busy sipping their morning coffee while they muse over moral philosophy—they're out there on the front lines of artificial intelligence, better prepared and more engaged than their peers from secular schools. According to the latest Holistic...
Continue Reading
Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...
Continue Reading
Navigating the Check Printing Landscape Let's dive right into the changing realities of the workspace. With remote work becoming the new standard, small businesses are juggling tighter budgets while trying to maintain smooth financial operations. It's a hard game, but here is where Halfpricesoft.com rolls out their newly upgraded multi-user ezCheckPrinting software,...
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of MoonLake Immunotherapeutics Class Action Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) have recently found themselves facing significant challenges. The disclosures regarding the company’s operations and the marketing of its products have prompted questions about the integrity of the information provided to shareholders. Why a Class Action? In a...
Continue Reading
BioCryst Concludes Successful Sale of European ORLADEYO Business In a significant move, BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has confirmed the successful sale of its European ORLADEYO business to Neopharmed Gentili. This transaction is valued at $250 million and includes the potential for up to $14 million in future milestones linked to sales across Central and...
Continue Reading
Overview of Investor Rights in the Edwards Lifesciences Case In today's financial landscape, safeguarding your investments is paramount. Edwards Lifesciences Corporation (NYSE: EW) has emerged as a notable player in the healthcare sector, particularly in innovative heart valve therapies. However, recent events have raised concerns among shareholders, prompting calls for...
Continue Reading
Revolutionizing Radiotherapy with Accuray Stellar Accuray, a leader in adaptive radiotherapy, has launched the Accuray Stellar™ Solution, which is designed to transform cancer care. This innovative solution offers an expansive toolbox that empowers clinical teams to adapt treatments to fit each patient's unique needs. Accuray's commitment to enhancing radiotherapy...
Continue Reading
Scale Computing Shines on Prestigious AI 100 Awards List Scale Computing, the market leader in edge computing and hyperconverged solutions, has recently made waves in the tech industry by being recognized on the annual CRN AI 100 list. This list marks a milestone as it celebrates companies that are at the forefront of innovation in artificial intelligence. Understanding...
Continue Reading